{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T01:17:50Z","timestamp":1770513470344,"version":"3.49.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,6,13]],"date-time":"2018-06-13T00:00:00Z","timestamp":1528848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,6,13]],"date-time":"2018-06-13T00:00:00Z","timestamp":1528848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Having demonstrated that apolipoprotein A-I (apoA-I) mimetic peptides ameliorate cancer in mouse models, we sought to determine the mechanism for the anti-tumorigenic function of these peptides. CT-26 cells (colon cancer cells that implant and grow into tumors in the lungs) were injected into wild-type BALB\/c mice. The day after injection, mice were either continued on chow or switched to chow containing 0.06% of a concentrate of transgenic tomatoes expressing the apoA-I mimetic peptide 6F (Tg6F). After four weeks, the number of lung tumors was significantly lower in Tg6F-fed mice. Gene expression array analyses of jejunum and lung identified Notch pathway genes significantly upregulated, whereas osteopontin (Spp1) was significantly downregulated by Tg6F in both jejunum and lung. In jejunum, Tg6F increased protein levels for Notch1, Notch2, Dll1, and Dll4. In lung, Tg6F increased protein levels for Notch1 and Dll4 and decreased Spp1. Tg6F reduced oxidized phospholipid levels (E06 immunoreactivity) and reduced 25-hydroxycholesterol (25-OHC) levels, which are known to inhibit Notch1 and induce Spp1, respectively. Notch pathway promotes anti-tumorigenic patrolling monocytes, while Spp1 facilitates pro-tumorigenic myeloid derived suppressor cells (MDSCs) formation. Tg6F-fed mice had higher numbers of patrolling monocytes in jejunum and in lung (p\u2009&lt;\u20090.02), and lower plasma levels of Spp1 with reduced numbers of MDSCs in jejunum and in lung (p\u2009&lt;\u20090.03). We conclude that Tg6F alters levels of specific oxidized lipids and 25-OHC to modulate Notch pathways and Spp1, which alter small intestine immune cells, leading to similar changes in lung that reduce tumor burden.<\/jats:p>","DOI":"10.1038\/s41598-018-26755-0","type":"journal-article","created":{"date-parts":[[2018,6,7]],"date-time":"2018-06-07T10:29:22Z","timestamp":1528367362000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Treating the Intestine with Oral ApoA-I Mimetic Tg6F Reduces Tumor Burden in Mouse Models of Metastatic Lung Cancer"],"prefix":"10.1038","volume":"8","author":[{"given":"Arnab","family":"Chattopadhyay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pallavi","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawoud","family":"Sulaiman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah R.","family":"Fogelman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Grijalva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Dubinett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tonya C.","family":"Wasler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manash K.","family":"Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramin","family":"Salehi-Rad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia J.","family":"Mack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3050-4168","authenticated-orcid":false,"given":"M. Luisa","family":"Iruela-Arispe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamad","family":"Navab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan M.","family":"Fogelman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srinivasa T.","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,13]]},"reference":[{"key":"26755_CR1","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1016\/j.jacc.2009.12.069","volume":"55","author":"H Jafri","year":"2010","unstructured":"Jafri, H., Alsheikh-Ali, A. A. & Karas, R. H. Baseline and on-treatment high-density lipoprotein cholesterol and the risk of cancer in randomized controlled trials of lipid-altering therapy. J Am Coll Cardiol. 55, 2846\u20132854 (2010).","journal-title":"J Am Coll Cardiol."},{"key":"26755_CR2","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.1002\/ijc.30013","volume":"138","author":"S Borgquist","year":"2016","unstructured":"Borgquist, S. et al. Apolipoproteins, lipids and risk of cancer. Int J Cancer. 138, 2648\u20132656 (2016).","journal-title":"Int J Cancer."},{"key":"26755_CR3","doi-asserted-by":"publisher","first-page":"19997","DOI":"10.1073\/pnas.1009010107","volume":"107","author":"F Su","year":"2010","unstructured":"Su, F. et al. Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer. Proc Natl Acad Sci. 107, 19997\u201320002 (2010).","journal-title":"Proc Natl Acad Sci."},{"key":"26755_CR4","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1039\/c0ib00147c","volume":"3","author":"F Gao","year":"2011","unstructured":"Gao, F. et al. L-5F, an apolipoprotein A-I mimetic, inhibits tumor angiogenesis by suppressing VEGF\/basic FGF signaling pathways. Interg Biol. 3, 479\u2013489 (2011).","journal-title":"Interg Biol."},{"key":"26755_CR5","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1002\/ijc.26079","volume":"130","author":"E Ganapathy","year":"2012","unstructured":"Ganapathy, E. et al. D-4F, an apoA-I mimetic peptide, inhibits proliferation and tumorgenicity of epithelial ovarian cancer cells by upregulating the antioxidant enzyme MnSOD. Int J Cancer. 130, 1071\u20131081 (2012).","journal-title":"Int J Cancer."},{"key":"26755_CR6","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1158\/1535-7163.MCT-11-0905","volume":"11","author":"F Su","year":"2012","unstructured":"Su, F. et al. HDL mimetics inhibit tumor development in both induced and spontaneous mouse models of colon cancer. Mol Cancer Ther. 11, 1311\u20131319 (2012).","journal-title":"Mol Cancer Ther."},{"key":"26755_CR7","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1124\/jpet.112.191544","volume":"342","author":"F Gao","year":"2012","unstructured":"Gao, F. et al. Apolipoprotein A-I mimetic peptides inhibit expression and activity of hypoxia-inducible factor-1\u03b1 in human ovarian cancer cell lines and a mouse ovarian cancer model. J Pharmacol Exp Ther. 342, 255\u2013262 (2012).","journal-title":"J Pharmacol Exp Ther."},{"key":"26755_CR8","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1073\/pnas.1213657110","volume":"110","author":"S Yang","year":"2013","unstructured":"Yang, S. et al. Biomimetic, synthetic HDL nanostructures for lymphoma. Proc Natl Acad Sci. 110, 2511\u20132516 (2013).","journal-title":"Proc Natl Acad Sci."},{"key":"26755_CR9","doi-asserted-by":"publisher","first-page":"3798","DOI":"10.4049\/jimmunol.1203194","volume":"190","author":"C Neyen","year":"2013","unstructured":"Neyen, C. et al. Macrophage scavenger receptor A promotes tumor progression in murine models of ovarian and pancreatic cancer. J Immunol. 190, 3798\u20133805 (2013).","journal-title":"J Immunol."},{"key":"26755_CR10","doi-asserted-by":"publisher","first-page":"e24461","DOI":"10.4161\/onci.24461","volume":"2","author":"C Neyen","year":"2013","unstructured":"Neyen, C., Mukhopadhyay, S., Gordon, S. & Hagemann, T. An apolipoprotein A-I mimetic targets scavenger receptor A on tumor-associated macrophages. A prospective anticancer treatment? OncoImmunology. 2, e24461 (2013).","journal-title":"OncoImmunology."},{"key":"26755_CR11","doi-asserted-by":"publisher","first-page":"21237","DOI":"10.1074\/jbc.M113.468967","volume":"288","author":"M Zamanian-Daryoush","year":"2013","unstructured":"Zamanian-Daryoush, M. et al. The cardioprotective protein apolipoprotein A1 promotes potent anti-tumorgenic effects. J Biol Chem. 288, 21237\u201321252 (2013).","journal-title":"J Biol Chem."},{"key":"26755_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/srep36387","volume":"6","author":"L Cedo","year":"2016","unstructured":"Cedo, L. et al. ApoA-I mimetic administration, but not increased apoA-I-containing HDL, inhibits tumour growth in a mouse model of inherited breast cancer. Scientific Reports. 6, 36387 (2016).","journal-title":"Scientific Reports."},{"key":"26755_CR13","doi-asserted-by":"publisher","first-page":"e00154","DOI":"10.1002\/prp2.154","volume":"3","author":"A Chattopadhyay","year":"2015","unstructured":"Chattopadhyay, A. et al. Efficacy of tomato concentrates in mouse models of dyslipidemia and cancer. Pharma Res Per. 3, e00154 (2015).","journal-title":"Pharma Res Per."},{"key":"26755_CR14","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1194\/jlr.M033555","volume":"54","author":"A Chattopadhyay","year":"2013","unstructured":"Chattopadhyay, A. et al. A novel approach to oral apoA-I mimetic therapy. J Lipid Res. 54, 995\u20131010 (2013).","journal-title":"J Lipid Res."},{"key":"26755_CR15","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1126\/science.aac9407","volume":"350","author":"RN Hanna","year":"2015","unstructured":"Hanna, R. N. et al. Patrolling monocytes control tumor metastasis to the lung. Science. 350, 985\u2013990 (2015).","journal-title":"Science."},{"key":"26755_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12597","volume":"7","author":"J Gamrekelashvili","year":"2016","unstructured":"Gamrekelashvili, J. et al. Regulation of monocyte cell fate by blood vessels mediated by Notch signaling. Nat. Commun. 7, 12597 (2016).","journal-title":"Nat. Commun."},{"key":"26755_CR17","doi-asserted-by":"publisher","first-page":"4706","DOI":"10.1158\/0008-5472.CAN-13-3334","volume":"74","author":"S Sangaletti","year":"2014","unstructured":"Sangaletti, S. et al. Osteopontin shapes immunosuppression in the metastatic niche. Cancer Res. 74, 4706\u201319 (2014).","journal-title":"Cancer Res."},{"key":"26755_CR18","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1189\/jlb.3MR1016-447R","volume":"102","author":"C Chiodoni","year":"2017","unstructured":"Chiodoni, C., Sangaletti, S. & Colombo, M. P. Matricellular proteins tune myeloid-derived suppressor cell recruitment and function in breast cancer. J Leukoc Biol. 102, 287\u2013292 (2017).","journal-title":"J Leukoc Biol."},{"key":"26755_CR19","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1084\/jem.20150603","volume":"212","author":"A Briot","year":"2015","unstructured":"Briot, A. et al. Endothelial NOTCH1 is suppressed by circulating lipids and antagonizes inflammation during atherosclerosis. J Exp Med. 212, 2147\u201363 (2015).","journal-title":"J Exp Med."},{"key":"26755_CR20","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/nri.2016.63","volume":"16","author":"CJ Binder","year":"2016","unstructured":"Binder, C. J., Papac-Milicevic, N. & Witztum, J. L. Innate sensing of oxidation-specific epitopes in health and disease. Nat Rev Immunol. 16, 485\u2013497 (2016).","journal-title":"Nat Rev Immunol."},{"key":"26755_CR21","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1172\/JCI117205","volume":"93","author":"KE Watson","year":"1994","unstructured":"Watson, K. E. et al. TGF-beta 1 and 25-hydroxycholesterol stimulate osteoblast-like vascular cells to calcify. J Clin Invest. 93, 2106\u201313 (1994).","journal-title":"J Clin Invest."},{"key":"26755_CR22","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1194\/jlr.M076554","volume":"58","author":"P Mukherjee","year":"2017","unstructured":"Mukherjee, P. et al. Transgenic tomatoes expressing the 6F peptide and ezetimibe prevent diet-induced increases of IFN-\u03b2 and cholesterol 25-hydroxylase in jejunum. J Lipid Res. 58, 1636\u20131647 (2017).","journal-title":"J Lipid Res."},{"key":"26755_CR23","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1194\/jlr.M067025","volume":"57","author":"D Meriwether","year":"2016","unstructured":"Meriwether, D. et al. Transintestinal transport of the anti-inflammatory drug 4F and the modulation of transintestinal cholesterol efflux. J Lipid Res. 57, 1175\u20131193 (2016).","journal-title":"J Lipid Res."},{"key":"26755_CR24","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1194\/jlr.M013144","volume":"52","author":"M Navab","year":"2011","unstructured":"Navab, M. et al. Intestine may be a major site of action for the apoA-I mimetic peptide 4F whether administered subcutaneously or orally. J Lipid Res. 52, 1200\u20131210 (2011).","journal-title":"J Lipid Res."},{"key":"26755_CR25","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1194\/jlr.M023523","volume":"53","author":"M Navab","year":"2012","unstructured":"Navab, M. et al. D-4F-mediated reduction in metabolites of arachidonic and linoleic acids in the small intestine is associated with decreased inflammation in low-density lipoprotein receptor-null mice. J Lipid Res. 53, 437\u2013446 (2012).","journal-title":"J Lipid Res."},{"key":"26755_CR26","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1194\/jlr.M049262","volume":"55","author":"Y Zhao","year":"2014","unstructured":"Zhao, Y. et al. In vivo efficacy of HDL-like nanolipid particles containing multivalent peptide mimetics of apolipoprotein A-I. J Lipid Res. 55, 2053\u20132063 (2014).","journal-title":"J Lipid Res."},{"key":"26755_CR27","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1194\/jlr.E053538","volume":"55","author":"GD Wool","year":"2014","unstructured":"Wool, G. D., Reardon, C. A. & Getz, G. S. Mimetic peptides of human apoA-I helix 10 get together to lower lipids and ameliorate atherosclerosis: is the action in the gut? J. Lipid Res. 55, 1983\u20131985 (2014).","journal-title":"J. Lipid Res."},{"key":"26755_CR28","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1194\/jlr.M064352","volume":"57","author":"A Chattopadhyay","year":"2016","unstructured":"Chattopadhyay, A. et al. Tg6F ameliorates the increase in oxidized phospholipids in the jejunum of mice fed unsaturated LysoPC or WD. J Lipid Res. 57, 832\u2013847 (2016).","journal-title":"J Lipid Res."},{"key":"26755_CR29","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nature07205","volume":"454","author":"A Mantovani","year":"2008","unstructured":"Mantovani, A., Allavena, P., Sica, A. & Balwill, F. Cancer-related inflammation. Nature. 454, 436\u2013444 (2008).","journal-title":"Nature."},{"key":"26755_CR30","first-page":"217","volume":"7","author":"M Perera","year":"2010","unstructured":"Perera, M. et al. TGF-\u03b21 Interactome: Metastasis and Beyond. Cancer Genomics & Proteomics. 7, 217\u2013230 (2010).","journal-title":"Cancer Genomics & Proteomics."},{"key":"26755_CR31","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s00109-013-1021-5","volume":"91","author":"HA Smith","year":"2013","unstructured":"Smith, H. A. & Kang, Y. The metastasis-promoting roles of tumor-associated immune cells. J Mol Med (Berl). 91, 411\u2013429 (2013).","journal-title":"J Mol Med (Berl)."},{"key":"26755_CR32","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nri3789","volume":"15","author":"T Kitamura","year":"2015","unstructured":"Kitamura, T., Qian, B.-Z. & Pollard, J. W. Immune cell promotion of metastasis. Nat Rev Immunol. 15, 73\u201386 (2015).","journal-title":"Nat Rev Immunol."},{"key":"26755_CR33","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1146\/annurev-med-051013-052304","volume":"66","author":"T Condamine","year":"2015","unstructured":"Condamine, T., Ramachandran, I., Youn, J.-I. & Gabrilovich, D. I. Regulation of tumor metastasis by myeloid-derived suppressor cells. Annu. Rev. Med. 66, 97\u2013110 (2015).","journal-title":"Annu. Rev. Med."},{"key":"26755_CR34","doi-asserted-by":"crossref","unstructured":"Vetsika, E.-K. et al. A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic\/predictive factor in untreated non-small lung cancer patients. J Immunol Res. 2014, Article ID659294 (2014).","DOI":"10.1155\/2014\/659294"},{"key":"26755_CR35","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.semcancer.2012.01.011","volume":"22","author":"S Ostrand-Rosenberg","year":"2012","unstructured":"Ostrand-Rosenberg, S., Sinha, P., Beury, D. W. & Clements, V. K. Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Semin Cancer Biol. 22, 275\u2013281 (2012).","journal-title":"Semin Cancer Biol."},{"key":"26755_CR36","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00262-013-1508-5","volume":"63","author":"C Meyer","year":"2014","unstructured":"Meyer, C. et al. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol Immunother. 63, 247\u2013257 (2014).","journal-title":"Cancer Immunol Immunother."},{"key":"26755_CR37","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00262-008-0523-4","volume":"58","author":"CM Diaz-Montero","year":"2009","unstructured":"Diaz-Montero, C. M. et al. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother. 58, 49\u201359 (2009).","journal-title":"Cancer Immunol Immunother."},{"key":"26755_CR38","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.intimp.2011.01.030","volume":"11","author":"J Finke","year":"2011","unstructured":"Finke, J., Ko, J., Rini, B., Rayman, P., Ireland, J. & Cohen, P. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Int Immunpharmacol. 11, 853\u2013858 (2011).","journal-title":"Int Immunpharmacol."},{"key":"26755_CR39","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00432-009-0634-0","volume":"136","author":"CY Liu","year":"2010","unstructured":"Liu, C. Y. et al. Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+\/CD14\u2212\/CD15+\/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol. 136, 35\u201345 (2010).","journal-title":"J Cancer Res Clin Oncol."},{"key":"26755_CR40","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1158\/1940-6207.CAPR-12-0275","volume":"6","author":"T Kimura","year":"2012","unstructured":"Kimura, T. et al. MUC1 Vaccine for individuals with advanced adenoma of the colon: A cancer immunoprevention feasibility study. Cancer Prev Res. 6, 18\u201326 (2013).","journal-title":"Cancer Prev Res."},{"key":"26755_CR41","doi-asserted-by":"publisher","first-page":"e87705","DOI":"10.1371\/journal.pone.0087705","volume":"9","author":"AA Tarhini","year":"2014","unstructured":"Tarhini, A. A. et al. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant Ipilimumab. PLoS ONE. 9, e87705 (2014).","journal-title":"PLoS ONE."},{"key":"26755_CR42","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/CJI.0000000000000005","volume":"37","author":"Z Wang","year":"2014","unstructured":"Wang, Z. et al. Association of myeloid-derived suppressor cells and efficacy of cytokine-induced killer cell immunotherapy in metastatic renal cell carcinoma patients. J. Immunother. 37, 43\u201350 (2014).","journal-title":"J. Immunother."},{"key":"26755_CR43","doi-asserted-by":"publisher","first-page":"5791","DOI":"10.4049\/jimmunol.181.8.5791","volume":"181","author":"JI Youn","year":"2008","unstructured":"Youn, J. I., Nagaraj, S., Collazo, M. & Gabrilovich, D. I. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol. 181, 5791\u20135802 (2008).","journal-title":"J Immunol."},{"key":"26755_CR44","doi-asserted-by":"publisher","first-page":"4233","DOI":"10.1182\/blood-2007-07-099226","volume":"111","author":"K Mavahedi","year":"2008","unstructured":"Mavahedi, K. et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood. 111, 4233\u20134244 (2008).","journal-title":"Blood."},{"key":"26755_CR45","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.coi.2010.01.021","volume":"22","author":"E Peranzoni","year":"2010","unstructured":"Peranzoni, E., Zilio, S., Marigo, I., Dolcetti, L., Zanovello, P., Mandruzzato, S. & Bronte, V. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol. 22, 238\u2013244 (2010).","journal-title":"Curr Opin Immunol."},{"key":"26755_CR46","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/cr.2015.144","volume":"26","author":"L Cassetta","year":"2016","unstructured":"Cassetta, L. & Pollard, J. W. Cancer immunosurveillance: role of patrolling monocytes. Cell Res. 26, 3\u20134 (2016).","journal-title":"Cell Res."},{"key":"26755_CR47","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/B978-0-12-397927-8.00007-5","volume":"65","author":"H Shao","year":"2012","unstructured":"Shao, H., Huang, Q. & Liu, Z. J. Targeting Notch signaling for cancer therapeutic intervention. Adv Pharmacol. 65, 191\u2013234 (2012).","journal-title":"Adv Pharmacol."},{"key":"26755_CR48","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/nrc.2016.145","volume":"17","author":"CS Nowell","year":"2017","unstructured":"Nowell, C. S. & Radtke, F. Notch as a tumour suppressor. Nat Rev Cancer. 17, 145\u2013159 (2017).","journal-title":"Nat Rev Cancer."},{"key":"26755_CR49","first-page":"14.1.1","volume":"111","author":"X Zhang","year":"2015","unstructured":"Zhang, X., Goncalves, R. & Mosser, D. M. The isolation and characterization of murine macrophages. Curr Protoc. Immunol. 111, 14.1.1\u201314.1.16 (2015).","journal-title":"Curr Protoc. Immunol."},{"key":"26755_CR50","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature14664","volume":"524","author":"J George","year":"2015","unstructured":"George, J. et al. Comprehensive genomic profiles of small cell lung cancer. Nature 524, 47\u201353 (2015).","journal-title":"Nature"},{"key":"26755_CR51","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1194\/jlr.M042051","volume":"54","author":"M Navab","year":"2013","unstructured":"Navab, M. et al. Transgenic 6F tomatoes act on the small intestine to prevent systemic inflammation and dyslipidemia caused by Western diet and intestinally derived lysophosphatidic acid. J. Lipid Res. 54, 3403\u20133418 (2013).","journal-title":"J. Lipid Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-26755-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-26755-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-26755-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T06:29:59Z","timestamp":1671604199000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-26755-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,13]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["26755"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-26755-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,13]]},"assertion":[{"value":"22 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Alan M. Fogelman, Mohamad Navab and Srinivasa T. Reddy are principals in Bruin Pharma and Alan M Fogelman is an officer in Bruin Pharma.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"9032"}}